268 related articles for article (PubMed ID: 37123954)
41. Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis.
Liu C; Fu Z; Jiang J; Chi K; Geng X; Mao Z; Song C; Sun G; Hong Q; Cai G; Chen X; Sun X
Front Med (Lausanne); 2021; 8():724456. PubMed ID: 34532333
[No Abstract] [Full Text] [Related]
42. The efficacy of Roxadustat for the treatment of anemia in dialysis dependent chronic kidney disease patients: an updated systematic review and meta-analysis of randomized clinical trials.
Abdelazeem B; Abbas KS; Shehata J; El-Shahat NA; Baral N; Savarapu P; Kunadi A
Ann Transl Med; 2021 Dec; 9(23):1714. PubMed ID: 35071408
[TBL] [Abstract][Full Text] [Related]
43. Changes in Metabolomic Profiles Induced by Switching from an Erythropoiesis-Stimulating Agent to a Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor in Hemodialysis Patients: A Pilot Study.
Watanabe K; Sato E; Mishima E; Moriya S; Sakabe T; Sato A; Fujiwara M; Fujimaru T; Ito Y; Taki F; Nagahama M; Tanaka K; Kazama JJ; Nakayama M
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628932
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and Safety of Vadadustat for Anemia in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
Xiong L; Zhang H; Guo Y; Song Y; Tao Y
Front Pharmacol; 2021; 12():795214. PubMed ID: 35115942
[No Abstract] [Full Text] [Related]
45. Iron Deficiency in Newly Referred Patients With Chronic Renal Failure.
Kitamura M; Yamashita H; Kuroki R; Fukuda H; Sawase A; Mukae H; Nishino T
Cureus; 2024 May; 16(5):e61076. PubMed ID: 38915962
[TBL] [Abstract][Full Text] [Related]
46. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism.
Ogawa C; Tsuchiya K; Maeda K
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769359
[TBL] [Abstract][Full Text] [Related]
47. Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia.
Li J; Haase VH; Hao CM
Kidney Dis (Basel); 2023 Jan; 9(1):1-11. PubMed ID: 36756084
[TBL] [Abstract][Full Text] [Related]
48. Roxadustat for Patients with Posttransplant Anemia: A Narrative Review.
Tang X; Liu F; Li Q; Mao J
Kidney Dis (Basel); 2024 Feb; 10(1):32-38. PubMed ID: 38322628
[TBL] [Abstract][Full Text] [Related]
49. Hypoxia-Inducible Factor Stabilizers in End Stage Kidney Disease: "Can the Promise Be Kept?".
Crugliano G; Serra R; Ielapi N; Battaglia Y; Coppolino G; Bolignano D; Bracale UM; Pisani A; Faga T; Michael A; Provenzano M; Andreucci M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830468
[TBL] [Abstract][Full Text] [Related]
50. Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors.
Locatelli F; Minutolo R; De Nicola L; Del Vecchio L
Drugs; 2022 Nov; 82(16):1565-1589. PubMed ID: 36350500
[TBL] [Abstract][Full Text] [Related]
51. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
[TBL] [Abstract][Full Text] [Related]
52. Zinc Supplementation Enhances the Hematopoietic Activity of Erythropoiesis-Stimulating Agents but Not Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors.
Takahashi A
Nutrients; 2024 Feb; 16(4):. PubMed ID: 38398842
[TBL] [Abstract][Full Text] [Related]
53. Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat.
Tang M; Zhu C; Yan T; Zhou Y; Lv Q; Chuan J
Front Pharmacol; 2021; 12():658079. PubMed ID: 34276361
[No Abstract] [Full Text] [Related]
54. Long-term treatment of chronic kidney disease patients with anemia using hypoxia-inducible factor prolyl hydroxylase inhibitors: potential concerns.
He J; Jia Z; Zhang A; Bai M
Pediatr Nephrol; 2024 Jan; 39(1):37-48. PubMed ID: 37284874
[TBL] [Abstract][Full Text] [Related]
55. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
[TBL] [Abstract][Full Text] [Related]
56. Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.
Kile M; Sudchada P
Int Urol Nephrol; 2021 Feb; 53(2):283-290. PubMed ID: 32770437
[TBL] [Abstract][Full Text] [Related]
57. Risk of infection in roxadustat treatment for anemia in patients with chronic kidney disease: A systematic review with meta-analysis and trial sequential analysis.
Chong S; Xie Q; Ma T; Xiang Q; Zhou Y; Cui Y
Front Pharmacol; 2022; 13():967532. PubMed ID: 36188528
[No Abstract] [Full Text] [Related]
58. Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases.
Miao M; Wu M; Li Y; Zhang L; Jin Q; Fan J; Xu X; Gu R; Hao H; Zhang A; Jia Z
Front Pharmacol; 2022; 13():837249. PubMed ID: 35281917
[TBL] [Abstract][Full Text] [Related]
59. Hypoxia inducible factor prolyl hydroxylase inhibitors: what a meta-analysis could tell us.
Locatelli F; Zoccali C
Clin Kidney J; 2024 Jan; 17(1):sfad229. PubMed ID: 38186887
[TBL] [Abstract][Full Text] [Related]
60. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis.
Liu J; Zhang A; Hayden JC; Bhagavathula AS; Alshehhi F; Rinaldi G; Kontogiannis V; Rahmani J
Pharmacol Res; 2020 May; 155():104747. PubMed ID: 32171893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
